Edition:
India

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.81USD
22 Jun 2018
Change (% chg)

$-0.01 (-1.10%)
Prev Close
$0.82
Open
$0.83
Day's High
$0.83
Day's Low
$0.80
Volume
96,109
Avg. Vol
74,522
52-wk High
$19.56
52-wk Low
$0.79

Chart for

About

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more... (more)

Overall

Beta: 0.37
Market Cap(Mil.): $31.68
Shares Outstanding(Mil.): 37.27
Dividend: --
Yield (%): --

Financials

BRIEF-Trovagene Files For Offering Of Up To $15 Mln Of Class A Units Of Common Stock And Up To $15 Mln Of Class B Units Of Common Stock

* TROVAGENE INC FILES FOR OFFERING OF UP TO $15.0 MILLION OF CLASS A UNITS OF COMMON STOCK AND UP TO $15.0 MILLION OF CLASS B UNITS OF COMMON STOCK - SEC FILING Source text: [https://bit.ly/2rAnkbg] Further company coverage:

10 May 2018

BRIEF-Trovagene Reports Q1 Loss Per Share $0.09

* TROVAGENE ANNOUNCES FIRST QUARTER 2018 HIGHLIGHTS AND FINANCIAL RESULTS

09 May 2018

BRIEF-Trovagene Reports Q4 Loss Per Share $0.06

* TROVAGENE ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 RESULTS

27 Feb 2018

BRIEF-Trovagene Completes Cycle-One Dosing In First Patient Enrolled In Phase 1B/2 Clinical Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF CYCLE-ONE DOSING IN FIRST PATIENT ENROLLED IN ITS PHASE 1B/2 CLINICAL TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:

06 Feb 2018

BRIEF-Trovagene Initiates Unite Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer

* TROVAGENE ANNOUNCES INITIATION OF UNITE PHASE 2 CLINICAL TRIAL OF PCM-075 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) Source text for Eikon: Further company coverage:

24 Jan 2018

Earnings vs. Estimates